Our present study demonstrates that although exhibiting similar clinical arthritic symptom, the immune pathogenesis of ACPA- and ACPA+ RA patients is quite different, which contributes to the histological, disease progression, and therapeutic strategy heterogeneity. Here, PRTN3 is linked to rheumatoid arthritis.